The nucleolus is the site of ribogenesis and therefore the functional site of proteins necessary for ribosomal RNA (rRNA) regulation, synthesis and processing [1]. Specific transcription factors and co-factors act as activators or repressors of rRNA transcription [2, 3] 
Introduction
The nucleolus is the site of ribogenesis and therefore the functional site of proteins necessary for ribosomal RNA (rRNA) regulation, synthesis and processing [1] . Specific transcription factors and co-factors act as activators or repressors of rRNA transcription [2, 3] . Activators of ribosomal gene (rDNA) [4, 5] .
We previously found that MTG16a/CBFA2T3 (hereafter referred to as MTG16a), a member of the Myeloid Translocation Gene (MTG) family of transcriptional repressors ( [6] , and references within), accumulates in the nucleolus and leads to the recruitment of specific HDACs to this compartment [7] . This observation made us hypothesize that MTG16a may play a role in rDNA transcriptional repression. Here we provide, for the first time, evidence that MTG16a can induce down-regulation of rRNA synthesis in human cells, and can significantly counteract the up-regulation of rRNA synthesis driven by the Pol I transcription activator MYC.
Increased rRNA synthesis/ribogenesis is a well-known hallmark of cancer cells, including breast cancer cells [8] [9] [10] [11] . MTG16 was reported to be lost in a fraction of breast tumours as a consequence of either loss of the 16q chromosome region containing the MTG16 locus, or epigenetic silencing due to aberrant DNA methylation [12] [13] [14] [15] . [16, 17] . 
In this study, we show that either MTG16a knockdown by RNA interference, or the sequestration of MTG16a outside the nucleolus of human breast epithelial cells, leads to an increase of rRNA synthesis and ribogenesis. Further, this is to our knowledge the first study showing that depriving the nucleolus of the rRNA-regulatory MTG16a function concomitantly affects ribogenesis and breast acinar morphogenesis, as it happens in the initial stages of breast tumourigenesis
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Quantitative chromatin immunoprecipitation (qChIP)
ChIP was performed using reagents purchased from Millipore, following the manufacturer's protocol. Endogenous MTG16 occupancy at the rDNA promoter was assessed by ChIP with an antibody against the MTG16 C-terminus [7] . 
Exogenous MTG16a-V5 occupancy at the rDNA promoter was assessed by ChIP with an anti-V5 antibody (Invitrogen) in combination with anti-MTG16 antibody. Control ChIPs were performed with non-specific IgGs (Millipore). The immunoprecipitated DNA was amplified by real-time PCR with primers specific for either a region within the rDNA promoter (region 'a') (sense: 5Ј-GTGTGTGGCTGCGATGGTG-3Ј; antisense: 5Ј-CCAAC-CTCTCCAGCGACAGG-3Ј) or a control region in the 28S rDNA (region 'c') (sense: 5Ј-GGACCCGAAAGATGGTGAACTA-3Ј; antisense: 5Ј-GAGAGCGCC -AGCTATCCTGAG-3Ј). Histone modifications were assessed by ChIP with either anti-Acetyl Histone H4 (AcH4) or anti-tri-methylated histone H3 lysine 9 (tri-met-H3K9) (Millipore). Control ChIPs were performed with non-specific IgGs (Millipore
Results
MTG16a localizes in the nucleolus and represses rRNA synthesis in Hela cells
We previously found that MTG16a, one of the two proteins encoded by the human MTG16 gene, accumulates in the nucleolus because it is endowed with a novel nucleolar localization signal [7] . 
MTG16a counteracts MYC-induced up-regulation of rRNA synthesis in human cells
The action of rDNA repressor complexes at the rDNA promoter region is counteracted by activator complexes [2, 3] . Recently, the oncoprotein MYC was shown to be involved in the activation of rRNA synthesis [24] [25] [26] (Fig. 2A, left) and an increased rRNA level ( Fig. 2A, right) relative to HFF control (HFF-Ctrl) fibroblasts. (Fig. 2B) and induces a significant (P Ͻ 0.05) decrease in both rRNA synthesis (Fig. 2C, left) and rRNA level (Fig. 2C, right) [15] , and second, nucleolar morphological changes that reflect defects in ribogenesis and rRNA synthesis are known to occur in the process of human breast tumourigenesis [16, 27] .
MTG16a-V5 transiently transfected in HFF-MYC fibroblasts accumulates in the nucleolus
We selected two immortalized, untransformed breast epithelial cells, HME1 and MCF10A, that express only MTG16a, but not MTG16b (Fig. 3A) . By immunocytochemistry with an antibody specific for MTG16 [7] , we found that in both cell lines endogenous MTG16a localizes both in the nucleoplasm and the nucleoli, which were identified with an antibody against the nucleolar protein B23 (Fig. 3B) . Consistently, transiently expressed exogenous MTG16a-V5 also localized in the nucleolus, as shown here for HME1 cells (Fig. 3C) . MTG16a-V5-transfected HME1 cells displayed both a significantly (P Ͻ 0.05) lower rRNA synthesis (Fig. 3D, left) and a significantly (P Ͻ 0.05) lower rRNA level (Fig. 3D, right) (Fig. 4A) showed a significant (P Ͻ 0.05) increase of both rRNA synthesis (Fig. 4B, left) and rRNA level (Fig. 4B, right) (Fig. 4C) , strengthening the conclusion that MTG16a can counteract the action of MYC on rRNA synthesis in different cell types. [15] , and a primary human breast epithelial strain HME31 [18] . We found that a lower level of MTG16 transcript in the breast cancer lines (Fig. 5, left) correlated with a significantly higher rRNA level (Fig. 5, right) (Fig. 6A, left) could be efficiently decreased with two distinct silencing sequences, shMTG16-1 and shMTG16-2 (Fig. 6A, right) . Next, we selected stable clones with MTG16a knockdown greater than 70% (Fig. 6B) . These clones displayed, in average, a significant increase in both rRNA synthesis (P Ͻ 0.01) (Fig. 6C, left) and rRNA level (P Ͻ 0.05) (Fig. 6C, right) relative to control clones. Similarly, stable MTG16a knockdown clones derived from MCF10A cells also showed a significantly higher rRNA level (Fig. S3A) . [28] , and typically increases during breast tumourigenesis [16, 27] . We estimated the AgNOR value by digitally evaluating both the size and the number of the AgNORs of silver stained cells. As shown in Figure 6D , the HME1-derived MTG16a knockdown clones displayed a significantly increased AgNOR value relative to the AgNOR value of control clones.
MTG16a counteracts MYC-induced up-regulation of rRNA synthesis in human breast epithelial cells
Next, we tested whether MTG16a, as in the HFF-MYC fibroblast model, can counteract MYC-induced rRNA up-regulation in breast epithelial cells. We stably transfected HME1 cells with either human MYC (HME1-MYC cells) or the cognate empty vector (HME1-ctrl cells). MYC-overexpressing HME1 cells
relative to control cells. MYC-induced up-regulation of rRNA synthesis in HME1 cells could be significantly (P Ͻ 0.05) decreased by transient expression of exogenous MTG16a
Fig. 3 MTG16a down-regulates rRNA synthesis in human breast epithelial cells. (A) RT-PCR showing that the two human breast epithelial cell lines MCF10A and HME1 express only MTG16a but not MTG16b (top); Western blot of nuclear extracts using anti-MTG16 antibody confirms MTG16a expression in both cell lines (bottom). (B) Immuncytochemistry showing that endogenous MTG16a, detected with anti-MTG16 (green), can localize both in the nucleoplasm and in the B23-positive nucleoli (red) of both HME1 and MCF10A. Nuclei are counterstained with DAPI (blue). (C) Exogenous MTG16a-V5 can be detected both in the nucleoplasm and the nucleolus by IC with anti-V5 antibody. (D) Transient expression of MTG16a-V5 in HME1 cells induces a significant (P Ͻ 0.05) decrease of both rRNA synthesis (left) and rRNA level (right). The bars in this figure represent the average of three determinations Ϯ standard deviation.
Low MTG16 expression is associated with an increased rRNA level in breast cancer cells
We tested the rRNA level of a few human breast cancer cell lines, including Hs578T, MDA-MB-468 and MDA-MB-231, previously reported to have a decreased MTG16 transcript level relative to normal breast tissue
relative to the untransformed breast epithelial cells (HME31). Thus, there seems to be an association between loss of MTG16a and increased rRNA level.
MTG16a knockdown in human breast epithelial cells induces an increase of rRNA synthesis and NORs
To test whether there is a causal link between a lower level of MTG16a transcript and up-regulation of rRNA synthesis in breast epithelial cells, we knocked down MTG16a in HME1 cells by RNA interference (RNAi) with either one of two MTG16-specific short hairpin sequences. First, we found that the expression of exogenous MTG16a-GFP protein in the nucleus/nucleolus of HME1
Next, we tested whether up-regulation of rRNA synthesis in the MTG16a knockdown clones was associated with an increase in the nucleolar organizer regions (NORs). The number and area of
Fig. 4 MTG16a counteracts MYC-induced up-regulation of rRNA synthesis in human breast epithelial cells. (A) Immunocytochemistry with anti-MYC antibody (left) followed by digital quantification (right) shows MYC overexpression in HME1 cells stably transfected with human MYC (HME1-MYC) relative to control HME1 cells transfected with the cognate empty vector. (B) HME1-MYC cells display significant (P Ͻ 0.05) upregulation of both rRNA synthesis (left) and rRNA level (right) relative to control cells carrying the cognate empty vector (HME1-ctrl). (C) Transient expression of exogenous
Fig. 6 MTG16a knockdown in human breast epithelial cells induces an increase of rRNA synthesis and NORs. (A) Exogenous MTG16a-GFP expression in HME1 cells (left) decreases significantly after RNA interference with shMTG16-1 and shMTG16-2 sequences (right). (B) HME1 clones carrying either pSuper-MTG16-1 (such as H16-1a and H16-1b) or pSuper-MTG16-2 (such as H16-2a and H16-2b) have a decreased MTG16a level relative to the HME1 parental cell line or a control clone (H-ctrl), as shown by
These findings support the conclusion that MTG16a knockdown in breast epithelial cells promotes both up-regulation of rRNA synthesis and increased ribogenesis.
Up-regulation of rRNA synthesis in breast epithelial cells is associated with impaired acinar morphogenesis
Untransformed breast epithelial cell lines, such as HME1 and MCF10A, are able to form mammary gland-like acini in 3D culture on reconstituted basement membrane [17, 29] . Under these conditions, untransformed cells grow as hollow acini lined by a polarized epithelium, while transformed cells typically display defects in acinar morphogenesis. By using this method, we found that both MYC overexpression (Fig. 7A ) and MTG16a knockdown (Fig. 7B ) in HME1 cells resulted in impaired acinar morphogenesis in more than 70% of the acini. Similarly, MTG16a knockdown clones derived from MCF10A cells also showed aberrant acinar morphogenesis (Fig. S3B) . Apparently, up-regulation of rRNA synthesis, either induced by MYC overexpression or MTG16a knockdown, correlates with morphological defects of the acini in 3D culture.
Sequestering MTG16a outside the nucleolus is sufficient to increase ribogenesis and disrupt 3D acinar morphogenesis
Whether there is a causal link between rRNA up-regulation and cell transformation, or vice versa is still debated [11] . [7] . By immunocytochemistry, we determined that while the wild-type MTG16a transfected in HME1 cells can localize both in the nucleoplasm and the nucleolus, the MTG16⌬1-3-GFP mutant cannot localize in the nucleolus (Fig. 8A, (Fig. 8A, middle) . By using an anti-MTG16 able to detect both endogenous MTG16a and exogenous MTG16⌬1-3, in combination with an antibody for the nucleolar marker B23, the nucleoli appeared to be depleted of endogenous MTG16a in cells transfected with MTG16⌬1-3-V5 (Fig. 8A, bottom) . (Fig. 8B) to assess ribogenesis and 3D acinar morphogenesis. ⌬1-3 cells displayed a significantly (P Ͻ 0.01) higher rRNA level compared to control cells (Fig. 8C) . Consistently, ⌬1-3 cells displayed also a significant increase (P Ͻ 0.001) in the AgNOR value (Fig. 8D) . Finally, by growing ⌬1-3 cells in 3D basement membrane culture, it was apparent that Ͼ 70% of the acini had an aberrant morphology (Fig. 8E) . Even if it cannot be discounted that the observed changes are in part due to the accumulation of MTG16a/MTG16⌬1-3 oligomers in the nucleoplasm, it seems that keeping MTG16a from functioning in the nucleolus is sufficient to recapitulate the effects observed in HME1 cells after MTG16a knockdown: increased rRNA level, increased ribogenesis and aberrant acinar morphogenesis. [5] . The NoRC complex acts by recruiting chromatinmodifying enzymes (e.g. histone deacetylases, HDACs) to induce a repressed chromatin status at the rDNA promoter [4, 5] . Previously, we reported that MTG16a can recruit HDACs into the nucleolus [7] . [30] .
To start to address this complex issue, we tested whether depriving HME1 cells of just the MTG16a nucleolar function is sufficient to recapitulate the two effects observed after MTG16a knockdown: increased rRNA level/ribogenesis and disruption of acinar morphogenesis. Based on our previous demonstration that MTG16a can be relocalized within the cell upon oligomerization with other MTG proteins [7], we set out to sequester MTG16a from the nucleolus into the nucleoplasm by expressing a mutant MTG16⌬1-3, which lacks the MTG16a nucleolar localization sequence, but maintains the MTG-MTG oligomerization domain
top). Based on immunocytochemistry of HME1 cells co-transfected with both MTG16⌬1-3-GFP and MTG16a-V5, MTG16⌬1-3 seemed capable of sequestering the wild-type MTG16a in the nucleoplasm
Next, we developed stable HME1 clones carrying MTG16⌬1-3-V5 (⌬1-3) and control clones (⌬-Ctrl) carrying the cognate empty vector
Fig. 7 Up-regulation of rRNA synthesis in breast epithelial cells is associated with impaired acinar morphogenesis. (A) Three-dimensional (3D) culture on reconstituted basement membrane followed by confocal microscopy shows that HME1-MYC cells are unable of proper acinar morphogenesis in more than 90% of the acini, as indicated by the inability to form hollow, polarized acini, with organized arrangement of the nuclei (blue), presence of an outer layer of integrin (green) and apical localization of the Golgi apparatus (red). (B) HME1 clones (H16-1a and H16-2a) knocked down for
V5-tagged wild-type MTG16a protein, containing the nucleolar localization sequence encoded by exons 1a-3, is targeted to the nucleolus of HME1 cells, while the GFP-tagged MTG16⌬1-3 deletion mutant protein, lacking the nucleolar localization sequence, cannot localize in the nucleolus (top). Immunocytochemistry of HME1 cells co-transfected with MTG16a-V5 and MTG16⌬1-3-GFP shows co-localization of the two exogenous proteins in the nucleoplasm (middle). Expression of MTG16⌬1-3-V5 in HME1 cells leads to depletion of endogenous MTG16a (detected with anti-MTG16, green) from the nucleoli (visualized with anti-B23, red). Nuclei are counterstained with DAPI (blue) (bottom). (B) Representative HME1 clone stably transfected with MTG16⌬1-3-V5 showing localization of the deletion mutant protein (red) in the nucleus (blue). (C)
Regulation of rRNA synthesis is determined by the opposing action of transcriptional repressor and activator complexes [2, 3] . The oncoprotein MYC is a known activator that promotes Pol I-driven transcription of ribosomal genes by directly interacting with the rDNA promoter region [24] [25] [26] [14, 15] , thus suggesting that MTG16 might act as a tumour suppressor [15] . By 
